Request your invitation for the Anglonordic Life Science Conference XV  at the link above.

Now entering its fifteenth year the conference will take place  in April or May 2018

The conference gives you the opportunity to meet decision makers at leading and upcoming drug discovery and technology companies from the UK and Anglonordic regions, along with investment firms from throughout Europe. The conference has a “by-invitation-only” policy. Service suppliers can attend as sponsors or exhibitors.

70 investment firms were registered to attend the May 2017 event, which started with an exclusive Reception, held at 58 Victoria Embankment, home of Scotland House.

The conference consists of five areas with simultaneous activities: the main conference room with focus on biotech investment, the technologies room, the one-to-one Meetings Area, the Exhibition Hall and the Salon Lounge quiet area.

The conference offers Meeting Mojo, the 1:1 online booking system used by 50,000 delegates across the world each year. Participants can browse profiles, set their own availability, request meetings, and promote their company to best advantage.

The conference media partner PharmaVentures offers 20 minute filmed interviews at the conference, free of charge.
PharmaVentures Insights is a TV series showcasing the best and the latest of the global life science industry. To date, over 500 senior executives from pharmaceutical, biotech and medtech industries have shared their compelling stories with a 15,000 online viewership. There is no cost associated with the interview and the footage will only be released with your approval. You can also share the interview on your marketing platforms at no cost. Contact Matt Royan at matt@pharmaventures.com to secure your 2018 spot or book using the 1:1 partnering system.

On the evening before the conference, delegates attend The Reception for focused networking. Numbers are limited and confirmation of attendance is required.

Organisations registered to attend the Anglonordic Life Science Conference in 2017:


4BIO Capital Partners, Advent Life Sciences, Albion Ventures, Angel investor, Animalcare Limited, Arcus Altor Ltd, Arix Bioscience, Belsize Asset Management, BioCity Group Limited, BioSeed Capital ltd, Caldwell Capital Limited, Cambridge Innovation Capital, Capricorn Venture Partners, CBC Investment Group, Certus, Clubb Capital Ltd, Deepbridge Capital, Epidarex Capital, Esperante, European Investment Fund, Ferghana Partners, Fort Rock Capital, GHO Capital, Harbert European Growth Capital, Health Enterprise East, IAG, Ignite Capital Partners, Inc., Industrifonden, Inventages, IP Group PLC, IPF Partners, Johnson & Johnson Innovation, Johnson and Johnson, Lilly, Locate in Limburg vzw, LSP, Medicon SD Ltd, Merck Ventures, Metellus AG, Molecular Warehouse, MVM Life Science Partners LLP, NeoMed, NetScientific, New Science Global Healthcare Fund, Newstock Capital, NIHR Office for Clinical Research Infrastructure, Norgine Ventures Management Limited, O2h Ventures Limited, Octopus Ventures, Pfizer Limited, Pharmalink AB, Rainbow Seed Fund, Rosetta Capital, Royal Bank of Canada (RBC), Ruffena Capital, SBA Ltd, SEHTA, Seventure, Spencer Stuart, SR One, Stifel, Sunstone Life Science Ventures, Tassi @ Co, Teijin Pharma Limited, Ventac Partners, Wellcome Trust, Wren Capital

Presenting Companies:

Active Needle Technology, Aglaris, Biotec Pharmacon, Brain Stimulation AB, Calcivis, Elasmogen Ltd, EnXray, Glide Technologies, Hiloprobe AB, LINK Medical Research, Macrophage Pharma, MGB Biopharma, MicroQuin, Nanogenic Solutions, OxStem, Predicare AB, ProAxsis, QureTech Bio AB, RefLab, ScioVR, Storm Therapeutics, TRANSPLANT BIOMEDICALS , SL, Tridentify AB, Unguis.


Acesion Pharma, Albumedix, Anglonordic Life Science Conference Committee, Ankrin Therapeutics, APL, Aptahem AB, Avilex Pharma, Bio Gateway, BioPartner UK, Biotech Umeå, British Embassy, Copenhagen, BTO, Business Birmingham, Business Sweden, Caldan Therapeutics, Catalonia Trade & Investment, Cell and Gene Therapy Catapult, Chronos Therapeutics, Department for International Trade, British Embassy Sweden, Dept of Bioengineering, Imperial College, DIT, Embassy of Belgium, EP Vantage, Epi-Endo Pharmaceuticals, Ezenze, Flanders Investment & Trade, F-star Biotechnology Ltd, Fusion Antibodies, Gabather AB, Gnosco AB, Stockholm, Government of Sweden, Informa Pharma Intelligence, Innovate UK, J A Kemp, Kymab, Life Science Partners (LSP), LINK Medical Research, LucyJRobertshaw, Lumina Adhesives AB, Göteborg, Marks & Clerk, Masters Speciality Pharma, MedCity, Medicon Valley Alliance, Mediconomics GmbH, MediWales, Medtech Insight, Merck KGaA, Monocl, Moon Fertility AB, Göteborg, MSD, MSD,  R&D Innovation Hub, Nature Research – Springer Nature, Neuro-Bio Ltd, NIHR Clinical Research Network, Oncopeptides AB, Oxford Genetics Ltd, Paras Biopharmacreuticals Finland Oy, Pharma Publications, PharmaVentures, Public Health England, Reapplix, Sahlgrenska Science Park, Scottish Development International, Shield Therapeutics, SidekickHealth, Smile, Spencer Stuart, Swecare, Symbiosis Pharmaceutical Services Ltd, The Cure Parkinson’s Trust, The Gurdon Institute, University of Cambridge, The Royal Veterinary College, TTO-UAB, UCL Business PLC, UK Department for International Trade, Umea Biotech Incubator, Val Jones PR, Xintela AB, Yaqrit (correct at last update).